TIS111D can affect bladder cancer cells by regulating epithelial-mesenchymal transition

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Bladder cancer remains a significant health concern with complex underlying molecular mechanisms.
• Understanding novel molecular players in bladder cancer progression is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of TIS111D (also known as AREG) in the development and progression of bladder cancer.
• To elucidate the molecular mechanisms by which TIS111D influences bladder cancer cell behavior, including proliferation and migration.

Main Methods:

• Immunohistochemistry, Western blot, and real-time PCR were used to assess TIS111D expression in bladder tumor tissues and cell lines.
• Functional assays (MTT, Transwell) were performed after TIS111D silencing to evaluate its impact on cell proliferation and migration.
• In vivo studies were conducted to confirm the role of TIS111D in tumor growth and metastasis.

Main Results:

• TIS111D expression was significantly elevated in bladder cancer tissues and cell lines compared to adjacent normal tissues.
• Silencing TIS111D inhibited bladder cancer cell proliferation and migration in vitro.
• TIS111D was found to regulate the expression of E-cadherin (E-cad) and N-cadherin (N-cad), key markers of epithelial-mesenchymal transition (EMT).
• In vivo experiments confirmed that TIS111D promotes bladder cancer growth and migration by modulating EMT.

Conclusions:

• TIS111D plays a critical role in promoting bladder cancer progression.
• The oncogenic function of TIS111D is mediated through the regulation of epithelial-mesenchymal transition (EMT).
• Targeting TIS111D may represent a potential therapeutic strategy for bladder cancer.